Aurinia Pharmaceuticals Inc. (AUPH) Is Worth Looking, Despite -44.81% Drop From High – Stocks Register
Home  »  Companies   »  Aurinia Pharmaceuticals Inc. (AUPH) Is Worth Looki...

Aurinia Pharmaceuticals Inc. (AUPH) Is Worth Looking, Despite -44.81% Drop From High

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) concluded the trading at $18.75 on Thursday, January 13 with a rise of 1.96% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $18.39 and 5Y monthly beta was reading 0.66 with its price kept floating in the range of $17.91 and $20.35 on the day. Considering stock’s 52-week price range provides that AUPH hit a high price of $33.97 and saw its price falling to a low level of $9.72 during that period. Over a period of past 1-month, stock came adding 4.11% in its value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


With its current market valuation of $2.59 billion, Aurinia Pharmaceuticals Inc. is set to declare its quarterly results on Feb 22, 2022 – Feb 28, 2022. Analysts are in estimates of -$0.27 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$1.41 for 2021 with estimates of that growing to -$0.41 in next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $22.87 million. They suggested that in the process company could generate revenue of as low as $20.5 million which could climb up to $26.7 million to hit a high.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review AUPH stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 50% Buy. Long term indicators are suggesting an average of Hold for it.

According to ratings assigned by 8 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 0 of them are recommending Aurinia Pharmaceuticals Inc. (AUPH) as a Hold, while 8 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.

Digging deeper we become aware of the PEG ratio of the AUPH stock which is currently positioned at 0. It further provides that stock’s current price level is -11.90% away from its 20-day simple moving average and is -18.80% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 39.23 while volatility remained at 8.63% over the past week which changes to 7.59% when measuring it over the past month. Beta is valued at 0.73, while measure of average true range or ATR is currently at 1.58. In predicting price targets of as low as $26.00 and as high as $40.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $33.63. Stock’s current price level is -38.67% above from estimated low price target while it is -113.33% below the estimated high; and even if the AUPH’s share succeeded to reach the median price of $34.00, then the outlook of -81.33% could come to the excitement of the investors.

In comparing Aurinia Pharmaceuticals Inc. (AUPH)’s stock with other industry players reveals that stock’s current price change of 1.96% and that of 29.67% over the past 12 months is in competing position with that of Regeneron Pharmaceuticals Inc. (REGN) which saw its stock price fall by -2.43% in the last trading and went through an increase of 18.96% in past 12-month trading. Industry’s another major player Aeterna Zentaris Inc. (AEZS) has fall -3.18% down in previous session, but over the past year has faced a fall of -47.18%, while Pieris Pharmaceuticals Inc. (PIRS) was also down -1.46% however its price remained floating in the green at 20.79% over the same period. Aurinia Pharmaceuticals Inc. has a P/E ratio of 0 against that of Regeneron Pharmaceuticals Inc.’s 9.84. On the other hand, the S&P 500 Index was down -1.42% in the last trading session while the Dow Jones Industrial closed the session lower at -0.49%.

Having a second look at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) provides that stock’s average daily trading volume for 3 months was 4.46 million. Number of outstanding shares of the stock stood at 128.44 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

The percentage of outstanding shares held by the insiders is 0.20% while it is 39.90% for the institutional holders. Subtraction of -18.01% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam